Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ).
Jacobio reported significant advances in its oncology pipeline, highlighted by Chinese regulatory approval of its KRAS G12C inhibitor glecirasib as a second-line monotherapy for NSCLC and its inclusion in the National Reimbursement Drug List. The company is also progressing a phase III first-line NSCLC study of glecirasib plus SHP2 inhibitor sitneprotafib, while expanding basket trials across multiple KRAS G12C-driven tumors and publishing key clinical results in leading medical journals.
In parallel, pan-KRAS inhibitor JAB-23E73 showed an encouraging safety profile and promising early efficacy in pancreatic cancer patients in a phase I trial in China, with a U.S. phase I study underway and a phase Ib/III trial cleared in combination with standard chemotherapy for first-line pancreatic ductal adenocarcinoma. Jacobio further strengthened its global positioning by signing a major licence and collaboration agreement with AstraZeneca for JAB-23E73, securing a US$100 million upfront payment and eligibility for up to US$1.915 billion in milestones plus tiered royalties, underscoring the strategic value of its KRAS franchise for investors and partners.
The most recent analyst rating on (HK:1167) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group is a clinical-stage biopharmaceutical company focused on oncology, developing targeted small-molecule therapies against KRAS and SHP2 mutations. The company concentrates on innovative treatments for non-small cell lung cancer, colorectal cancer, pancreatic cancer and other solid tumors, with a growing emphasis on global partnerships and commercialization in China and abroad.
Average Trading Volume: 4,308,086
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.82B
For detailed information about 1167 stock, go to TipRanks’ Stock Analysis page.